SLC5A2 and cervical carcinoma: In our study, patients with T2DM diagnosed with cervical cancer within 6 months of SGLT2 inhibitor use were excluded to ensure a clear temporal relationship between SGLT2 inhibitor use and the occurrence of cervical cancer.